New Jersey Assembly Bill A1654

New Jersey 2022-2023 Regular Session

• Introduced: 1/11/22
• Refer: 1/11/22

Caption

Includes screening for toxoplasmosis in newborn screening program.

Impact

The expansion of the testing regime is designed to improve health outcomes for infants born in the state by allowing for the timely identification of toxoplasmosis. This disorder, if not detected, can lead to significant health issues, including mental retardation, seizures, and impaired eyesight. The public health implications of this legislation reinforce the state's proactive approach to safeguarding infant health. Furthermore, it mandates the creation of a program to follow up on any positive cases identified through the screenings, ensuring that families receive necessary support and intervention.

Summary

Assembly Bill A1654 aims to enhance the newborn screening program in New Jersey by including testing for toxoplasmosis, a parasitic infection that can have severe health implications for newborns. Currently, the state screens for 54 disorders, and this bill seeks to add another critical disorder to that list, highlighting the importance of early detection and intervention. The bill emphasizes the state's commitment to public health and aims to ensure that newborns receive comprehensive screenings that can prevent permanent disabilities.

Contention

While the bill is largely seen as a positive step for public health, there may be points of contention regarding the implementation of additional fees for testing and potential objections based on religious beliefs. Parents have the right to refuse testing on religious grounds, which is an important consideration in the bill's implementation. Additionally, stakeholders may discuss the availability of resources to carry out the expanded testing and the capacity of the state's healthcare system to respond to the additional burden of testing and subsequent healthcare needs.